• Profile

Testosterone responders to continuous androgen deprivation therapy exhibit considerable variations in testosterone levels on follow-up: implications for clinical practice

The Journal of Urology Aug 15, 2017

Sayyid RK, et al. – The physicians conducted this work to determine whether continuous androgen deprivation therapy users achieving testosterone levels <0.7 nmol/L illustrate subsequent testosterone level elevations on follow–up and whether such events predict worse oncologic outcomes. Taking into account a large series of patients and an important follow–up period, continuous androgen deprivation therapy users having initial testosterone levels <0.7 nmol/L frequently exhibit subsequent elevations in serum testosterone levels. Moreover, such occurences should not trigger an immediate response from physicians as these events are prognostically insignificant with regards to oncologic outcomes, and patients eventually re–establish levels <0.7 nmol/L.

  • Researchers designed a random, retrospective study including a sample of 514 prostate cancer patients treated with continuous androgen deprivation therapy and having serum testosterone levels <0.7 nmol/L, at the University Health Network between 2007–2016.
  • In this research, patients were followed from date of first testosterone level <0.7 nmol/L till progression to castrate resistance, death, or end of study period.
  • Study outcomes were occurrence of testosterone level elevations >0.7, >1.1, and >1.7 nmol/L and progression to castrate–resistant state.
  • They used survival curves to determine rates of occurrence of testosterone level elevations.
  • They applied multivariate Cox regression analysis to evaluate whether occurrence of elevations predicts progression to castrate–resistance.

  • 74 years was the median age.
  • Median follow–up was 20.3 months was the median.
  • The data showed that 82%, 45%, and 18% of patients had subsequent testosterone levels >0.7, >1.1, and >1.7 nmol/L within five years of follow–up, respectively, and 96–100% of such patients subsequently re–established levels <0.7 nmol/L within five years.
  • It was showed that none of the patient baseline characteristics were associated with occurrence of elevations.
  • In addition, occurrence of elevations was not a significant predictor of progression to castrate–resistant state.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen